Table 3.
Clinical trials of therapeutic vaccines for HCC the last three years.
| NCT ID | Target | Phase | Interventions | Country |
|---|---|---|---|---|
| NCT04251117 | Neoantigen | 1, 2 | personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) | US, New Zealand |
| NCT04912765 | Neoantigen | 2 | Dendritic Cell Vaccine and Nivolumab | Singapore |
| NCT04248569 | DNAJB1-PRKACAfusion kinase | 1 | Peptide Vaccine Combined With Nivolumab and Ipilimumab | US |
| NCT03674073 | Neoantigen | 1 | Dendritic Cell Vaccine Combined With Microwave Ablation | China |
| NCT04147078 | Neoantigen | 1 | Dendritic Cell Vaccine | China |
| NCT04317248 | NA | 2 | Multiple Signals loaded Dendritic Cells Vaccine | China |
| NCT04246671 | HER-2 | 1, 2 | TAEK-VAC-HerBy vaccine: Modified Vaccinia Ankara-BN (MVA-BN) virus | US |
| NCT03942328 | Streptococcuspneumoniae | 1 | Autologous Dendritic Cells and Pneumococcal 13-valent Conjugate Vaccine | US |
NA, Not available.